Reduction of Cx43 hemichannel activity through treatment with Gap19 selective peptide mimetic inhibitor, improved myocardial ischemia, reperfusion, and cardiac damage by lowering the occurrence of arrhythmias, metabolic injury, and mortality16,23,27. The gene discussed is GJA1; the disease is cardiac arrhythmia.